Nancy L. Snyderman's most recent trade in Alkermes plc was a trade of 8,013 Ordinary Shares done . Disclosure was reported to the exchange on May 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 8,013 | 12,652 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 8,013 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.61 per share. | 31 May 2025 | 1,924 | 10,728 (0%) | 0% | 30.6 | 58,894 | Ordinary Shares |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 13,474 | 13,474 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 6,142 | 6,142 | - | - | Restricted Stock Unit Award | |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 32,000 | 32,000 | - | - | Restricted Stock Units | |
| Axonics Inc | Nancy L. Snyderman | Director | Sale or transfer of securities back to the company at price $ 71.00 per share. | 15 Nov 2024 | 14,944 | 0 (0%) | 0% | 71 | 1,061,024 | Common Stock |
| Axonics Inc | Nancy L. Snyderman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Nov 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axonics Inc | Nancy L. Snyderman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Nov 2024 | 4,167 | 0 | - | - | Stock Option (Right to Buy) | |
| Axonics Inc | Nancy L. Snyderman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2024 | 5,000 | 14,944 (0%) | 0% | 0 | Common Stock | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 6,104 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 4,639 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 548 | 27,948 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 448 | 22,848 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 350 | 17,850 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 324 | 16,524 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 284 | 14,484 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 256 | 13,079 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 230 | 11,739 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 22,213 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Nancy L. Snyderman | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 20,783 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 12,732 | 12,732 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 5,985 | 5,985 | - | - | Restricted Stock Unit Award | |
| Axonics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 3,000 | 19,944 (0%) | 0% | 0 | Common Stock | |
| Axonics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2022 | 2,100 | 16,944 (0%) | 0% | 0 | Common Stock | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 11,554 | 11,554 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 5,957 | 5,957 | - | - | Restricted Stock Unit Award | |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,250 | 7,250 | - | - | Stock Option | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 16,951 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.19 per share. | 14 Jun 2022 | 695 | 16,256 (0%) | 0% | 27.2 | 18,897 | Ordinary Shares |
| Alkermes plc | Nancy L. Snyderman | Director | Purchase of securities on an exchange or from another person at price $ 23.43 per share. | 04 Mar 2022 | 427 | 9,366 (0%) | 0% | 23.4 | 10,005 | Ordinary Shares |
| Axonics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2021 | 2,261 | 14,844 (0%) | 0% | 0 | Common Stock | |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,250 | 7,250 | - | - | Stock Option | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 6,104 | 6,104 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Nancy L. Snyderman | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.92 per share. | 20 May 2021 | 1,404 | 4,700 (0%) | 0% | 21.9 | 30,776 | Ordinary Shares |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Purchase of securities on an exchange or from another person at price $ 9.72 per share. | 16 Dec 2020 | 1,025 | 1,025 | - | 9.7 | 9,963 | Common Stock |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 11,509 | 11,509 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 5,578 | 5,578 | - | - | Restricted Stock Unit Award | |
| Lyra Therapeutics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 14,500 | 14,500 | - | - | Stock Option | |
| Axonics Inc | Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2020 | 3,500 | 12,583 (0%) | 0% | 0 | Common Stock |